Effects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys
Authors
Keywords
-
Journal
TOXICOLOGIC PATHOLOGY
Volume 43, Issue 7, Pages 1004-1014
Publisher
SAGE Publications
Online
2015-06-10
DOI
10.1177/0192623315588999
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances
- (2016) Meena Asmar et al. Current Opinion in Endocrinology Diabetes and Obesity
- Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study
- (2015) R. S. Weinstock et al. DIABETES OBESITY & METABOLISM
- The Human GLP-1 Analogs Liraglutide and Semaglutide: Absence of Histopathological Effects on the Pancreas in Nonhuman Primates
- (2014) C. F. Gotfredsen et al. DIABETES
- Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
- (2014) Guillermo Umpierrez et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
- (2014) Carol Wysham et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
- (2014) Michael Nauck et al. DIABETES CARE
- Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies
- (2014) S. Bonner-Weir et al. DIABETES OBESITY & METABOLISM
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- High fat diet and GLP-1 drugs induce pancreatic injury in mice
- (2014) Rodney Rouse et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Incretin Therapy and Islet Pathology: A Time for Caution
- (2013) S. E. Kahn DIABETES
- Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
- (2013) A. E. Butler et al. DIABETES
- Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
- (2013) D. J. Drucker DIABETES
- A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks
- (2013) M. A. Nauck DIABETES CARE
- A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 therapies safe?
- (2013) P. C. Butler et al. DIABETES CARE
- The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis
- (2012) Niels Vrang et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Pancreatitis: A Potential Complication of Liraglutide?
- (2012) Andrea S Franks et al. ANNALS OF PHARMACOTHERAPY
- Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12DMouse Model
- (2012) Belinda Gier et al. DIABETES
- The Human GLP-1 Analog Liraglutide and the Pancreas
- (2012) Niels C.B. Nyborg et al. DIABETES
- GLP-1–Based Therapies and the Exocrine Pancreas: More Light, or Just More Heat?
- (2012) Edwin A.M. Gale DIABETES
- Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study
- (2012) G. Grunberger et al. DIABETIC MEDICINE
- Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study
- (2012) M. Wenten et al. DIABETIC MEDICINE
- A Monoclonal Antibody-GDNF Fusion Protein Is Not Neuroprotective and Is Associated with Proliferative Pancreatic Lesions in Parkinsonian Monkeys
- (2012) Sachiko Ohshima-Hosoyama et al. PLoS One
- LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects
- (2011) P. Barrington et al. DIABETES OBESITY & METABOLISM
- The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study
- (2011) G. E. Umpierrez et al. DIABETES OBESITY & METABOLISM
- A cohort study of acute pancreatitis in relation to exenatide use
- (2011) D. D. Dore et al. DIABETES OBESITY & METABOLISM
- A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
- (2011) P. Barrington et al. DIABETES OBESITY & METABOLISM
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents
- (2010) Krystyna Tatarkiewicz et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis
- (2010) R. Garg et al. DIABETES CARE
- Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes
- (2010) C. J. Girman et al. DIABETES OBESITY & METABOLISM
- Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
- (2010) Wolfgang Glaesner et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
- (2010) S. S. Engel et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Incidences and Range of Spontaneous Findings in Control Cynomolgus Monkeys (Macaca fascicularis) Used in Toxicity Studies
- (2010) Ronnie Chamanza et al. TOXICOLOGIC PATHOLOGY
- Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
- (2009) David D. Dore et al. CURRENT MEDICAL RESEARCH AND OPINION
- Glucagon-Like Peptide-1 Receptor Activation Modulates Pancreatitis-Associated Gene Expression But Does Not Modify the Susceptibility to Experimental Pancreatitis in Mice
- (2009) J. A. Koehler et al. DIABETES
- Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study
- (2009) R. A. Noel et al. DIABETES CARE
- Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
- (2009) J. S. Nachnani et al. DIABETOLOGIA
- Pancreatic Duct Glands Are Distinct Ductal Compartments That React to Chronic Injury and Mediate Shh-Induced Metaplasia
- (2009) Oliver Strobel et al. GASTROENTEROLOGY
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now